双醋瑞因对比安慰剂治疗伴积液-滑膜炎的膝骨关节炎的随机对照试验研究方案(DICKENS)
本研究为多中心、随机、安慰剂对照双盲试验,计划在澳大利亚四城市招募260例伴显著膝痛且MRI检出积液-滑膜炎的临床膝骨关节炎患者,随机接受双醋瑞因50mg每日两次或安慰剂治疗24周。主要结局为24周时100mm视觉模拟量表评估的膝痛改善,次要结局包括积液-滑膜炎体积和半定量MRI测量改善及多个时间点膝痛改善。研究旨在为双醋瑞因对炎性表型膝骨关节炎的疗效提供高质量证据。
要点
- 拟招募260例伴显著膝痛和MRI检出积液-滑膜炎的临床膝骨关节炎患者。
- 随机接受双醋瑞因50mg每日两次或安慰剂治疗24周。
- 主要结局为24周时100mm VAS评估的膝痛改善。
核心结论
- 本研究旨在提供高质量证据以确定双醋瑞因是否改善伴积液-滑膜炎的骨关节炎患者的疼痛、改变疾病轨迹并延缓疾病进展。
- 若双醋瑞因被证实有效,可能使高达60%的炎性表型膝骨关节炎患者显著获益。
研究设计与样本
- 多中心、随机、安慰剂对照双盲试验,计划在澳大利亚霍巴特、墨尔本、阿德莱德和珀斯招募260例患者。
- 纳入临床膝骨关节炎、显著膝痛且MRI检出积液-滑膜炎的患者,随机分配接受双醋瑞因50mg每日两次或相同安慰剂治疗24周。
- 在筛选时和干预24周后对研究膝进行MRI检查。
- 主要分析为意向性治疗分析,符合方案分析作为次要分析。
关键数值与推荐
- 主要结局为24周时100mm视觉模拟量表(VAS)评估的膝痛改善。
- 次要结局包括24周内MRI测量的积液-滑膜炎体积(ml)和半定量(全器官磁共振成像评分,0-3分)改善,以及第4、8、12、16和20周时膝痛(VAS)改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an unmet need for treatments for knee osteoarthritis (OA). Effusion-synovitis is a common inflammatory phenotype of knee OA and predicts knee pain and structural degradation. Anti-inflammatory therapies, such as diacerein, may be effective for this phenotype. While diacerein is recommended for alleviating pain in OA patients, evidence for its effectiveness is inconsistent, possibly because studies have not targeted patients with an inflammatory phenotype. Therefore, we will conduct a multi-centre, randomised, placebo-controlled double-blind trial to determine the effect of diacerein on changes in knee pain and effusion-synovitis over 24 weeks in patients with knee OA and magnetic resonance imaging (MRI)-defined effusion-synovitis. METHODS: We will recruit 260 patients with clinical knee OA, significant knee pain, and MRI-detected effusion-synovitis in Hobart, Melbourne, Adelaide, and Perth, Australia. They will be randomly allocated to receive either diacerein (50mg twice daily) or identical placebo for 24 weeks. MRI of the study knee will be performed at screening and after 24 weeks of intervention. The primary outcome is improvement in knee pain at 24 weeks as assessed by a 100-mm visual analogue scale (VAS). Secondary outcomes include improvement in volumetric (ml) and semi-quantitative (Whole-Organ Magnetic Resonance Imaging Score, 0-3) measurements of effusion-synovitis using MRI over 24 weeks, and improvement in knee pain (VAS) at 4, 8, 12, 16, and 20 weeks. Intention-to-treat analyses of primary and secondary outcomes will be performed as the primary analyses. Per protocol analyses will be performed as the secondary analyses. DISCUSSION: This study will provide high-quality evidence to determine whether diacerein improves pain, changes disease trajectory, and slows disease progression in OA patients with effusion-synovitis. If diacerein proves effective, this has the potential to significantly benefit the substantial proportion (up to 60%) of knee OA patients with an inflammatory phenotype. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry ACTRN12618001656224 . Registered on 08 October 2018.
引用
- Cai G, Jones G, Cicuttini FM, et al. Study protocol for a randomised controlled trial of diacerein versus placebo to treat knee osteoarthritis with effusion-synovitis (DICKENS). Trials. 2022. PMID: 36089595. doi:10.1186/s13063-022-06715-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。